<a href="https://laohu8.com/S/KRRO">Korro Bio</a> reports third quarter results and provides pipeline updates
Korro Bio Inc. reported third quarter 2025 financial results, with cash, cash equivalents, and marketable securities totaling $102.5 million as of September 30, 2025, down from $163.1 million at December 31, 2024. The company expects its cash position to fund operations into the second half of 2027. Collaboration revenue for the quarter was $1.1 million, compared to no collaboration revenue in the same period of 2024, due to income from Korro's collaboration with Novo Nordisk. Research and development expenses were $13.8 million, down from $16.0 million in the prior year period, mainly due to decreased KRRO-110 and pre-development candidate expenses. General and administrative expenses were $6.5 million, compared to $7.3 million in the third quarter of 2024, primarily reflecting lower professional services costs. Net loss for the quarter was $18.1 million, compared to $21.0 million in the same period last year. Business developments included the announcement that KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency patients, though not at projected levels, leading to a pivot to GalNAc delivery with a development candidate nomination expected in the first half of 2026. The company also nominated KRRO-121, a candidate for hyperammonemia, and announced the resignation of Chief Medical Officer Dr. Kemi Olugemo, effective November 12, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-277556), on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.